RESUMEN
The adenovirus E1A gene product trans-activates a number of viral and cellular promoters. The mechanism for this transcriptional induction was investigated with an in vivo exoIII mapping technique to assay for proteins that interact with an E1A-inducible promoter. A protein bound to the early E2 promoter was detected in wild-type infected cells. In the absence of E1A induction, specific interactions at the promoter could not be detected, as indicated by the absence of an exoIII-protected fragment. However, if conditions were established that allowed transcription of the E2 gene in the absence of E1A, the same exoIII protection was observed as was found in the presence of E1A. These results suggest a model in which the efficient utilization of the E2 promoter is mediated by a cellular transcription factor. In the absence of E1A, the interaction can take place, but slowly and inefficiently in comparison with the interaction in the presence of E1A.
Asunto(s)
Proteínas de Unión al ADN/metabolismo , Proteínas Oncogénicas Virales/genética , Regiones Promotoras Genéticas , Factores de Transcripción/metabolismo , Transcripción Genética , Proteínas Precoces de Adenovirus , Cromatina/ultraestructura , ADN Viral/genética , Exodesoxirribonucleasas/metabolismo , Células HeLa , HumanosRESUMEN
The human adenovirus serotype 5 (Ad5) is used widely for applications in human gene therapy. Cellular attachment of Ad5 is mediated by binding of the carboxyl-terminal knob of its fiber coat protein to the Coxsackie adenovirus receptor (CAR) protein. However, Ad5 binding to CAR hampers the development of adenovirus vectors capable of specifically targeting (diseased) tissues or organs. Through sequence analysis and mutagenesis, a conserved receptor-binding region was identified on the side of three divergent CAR-binding knobs. The feasibility of simultaneous CAR ablation and redirection of an adenovirus to a new receptor is demonstrated.
Asunto(s)
Adenovirus Humanos/química , Proteínas de la Cápside , Cápside/química , Cápside/metabolismo , Receptores Virales/metabolismo , Adenovirus Humanos/metabolismo , Secuencia de Aminoácidos , Sitios de Unión , Cápside/genética , Línea Celular , Secuencia Conservada , Proteína de la Membrana Similar al Receptor de Coxsackie y Adenovirus , Vectores Genéticos , Humanos , Modelos Moleculares , Mutagénesis Sitio-Dirigida , Mutación Puntual , Conformación Proteica , Estructura Secundaria de Proteína , Eliminación de Secuencia , Transfección , Células Tumorales CultivadasRESUMEN
cGMP has a short-term effect on smooth muscle tone and a longer-term effect on responses to chronic drug treatment or proliferative signals. cGMP-Phosphodiesterase type 5 (PDE5) hydrolizes cGMP, and the result is smooth muscle contraction. PDE5 is a relatively novel therapeutic target of various diseases, such as erectile dysfunction and pulmonary hypertension. The most intensively examined and marketed PDE5 inhibitor was sildenafil (Viagra) but recently vardenafil (Levitra) and tadalafil (Cialis) were launched with beneficial ADME parameters and PDE5 selectivity. The increasing interest in PDE5 inhibition made it reasonable to collect the available inhibitory data from the scientific literature and set up a structure-activity relationship study. Chemical structures of 438 compounds and their cGMP-PDE5 inhibitory data (IC50) were collected from recently published articles. In this paper physiology, regulation and inhibition of PDE5 (and briefly other PDE-s) are discussed and inhibitors are tabulated by the core structures. Finally, a general QSAR model built from these data is presented. All data used in the QSAR study were summarized in a Supplement (for description please see the online version of the article).
Asunto(s)
Inhibidores de Fosfodiesterasa 5 , Inhibidores de Fosfodiesterasa/química , Inhibidores de Fosfodiesterasa/farmacología , Catálisis , Fosfodiesterasas de Nucleótidos Cíclicos Tipo 5/clasificación , Fosfodiesterasas de Nucleótidos Cíclicos Tipo 5/metabolismo , Humanos , Modelos Biológicos , Relación Estructura-ActividadRESUMEN
The DF3/MUC1 gene is aberrantly overexpressed in human breast and other carcinomas. Previous studies have demonstrated that the DF3/MUC1 promoter/enhancer confers selective expression of diverse transgenes in MUC1-positive breast cancer cells. In this study, we show that an adenoviral vector (Ad.DF3-E1) in which the DF3/MUC1 promoter drives expression of E1A selectively replicates in MUC1-positive breast cancer cells. We also show that Ad.DF3-E1 infection of human breast tumor xenografts in nude mice is associated with inhibition of tumor growth. In contrast to a replication-incompetent adenoviral vector that infects along the injection track, Ad.DF3-E1 infection was detectable throughout the tumor xenografts. To generate an Ad.DF3-E1 vector with the capacity for incorporating therapeutic products, we inserted the cytomegalovirus (CMV) promoter upstream of the TNF cDNA. Infection with Ad.DF3-E1/CMV-TNF was associated with selective replication and production of TNF in cells that express MUC1. Moreover, treatment of MUC1-positive, but not MUC1-negative, xenografts with a single injection of Ad.DF3-E1/CMV-TNF was effective in inducing stable tumor regression. These findings demonstrate that the DF3/MUC1 promoter confers competence for selective replication of Ad.DF3-E1 in MUC1-positive breast tumor cells, and that the antitumor activity of this vector is potentiated by integration of the TNF cDNA.
Asunto(s)
Adenoviridae/genética , Neoplasias de la Mama/química , Neoplasias de la Mama/genética , Mucina-1/genética , Replicación Viral/genética , Proteínas E1A de Adenovirus/genética , Proteínas E1A de Adenovirus/metabolismo , Animales , Biomarcadores de Tumor/análisis , Biomarcadores de Tumor/genética , Neoplasias de la Mama/terapia , División Celular , Citomegalovirus/genética , Femenino , Citometría de Flujo , Regulación Neoplásica de la Expresión Génica , Terapia Genética , Histocitoquímica , Humanos , Ratones , Ratones Desnudos , Mucina-1/análisis , Trasplante de Neoplasias , Regiones Promotoras Genéticas , Células Tumorales Cultivadas , Factor de Necrosis Tumoral alfa/genética , Factor de Necrosis Tumoral alfa/metabolismo , Factor de Necrosis Tumoral alfa/uso terapéuticoRESUMEN
Most evidence indicates that nitric oxide plays a role in normal wound repair; however, involvement of inducible nitric oxide synthase (iNOS) has not been established. Experiments were carried out to determine the requirement for iNOS in closing excisional wounds. Wound closure was delayed by 31% in iNOS knockout mice compared with wild-type animals. An identical delay in wound closure was observed in wild-type mice given a continuous infusion of the partially selective iNOS inhibitor N6-(iminoethyl)-L-lysine. Delayed wound healing in iNOS-deficient mice was completely reversed by a single application of an adenoviral vector containing human iNOS cDNA (AdiNOS) at the time of wounding. Reverse transcription PCR identified iNOS mRNA expression in wild-type mice peaking 4-6 d after wounding, and confirmed expression of human iNOS in the adenoviral vector containing human iNOS cDNA-treated animals. These results establish the key role of iNOS in wound closure, and suggest a gene therapy strategy to improve wound healing in iNOS-deficient states such as diabetes, and during steroid treatment.
Asunto(s)
Técnicas de Transferencia de Gen , Óxido Nítrico Sintasa/genética , Cicatrización de Heridas , Células 3T3 , Actinas/genética , Actinas/metabolismo , Adenoviridae/genética , Animales , Células Cultivadas , ADN Complementario/genética , Inhibidores Enzimáticos/farmacología , Expresión Génica , Terapia Genética/métodos , Humanos , Lisina/análogos & derivados , Lisina/farmacología , Ratones , Ratones Noqueados , Óxido Nítrico/metabolismo , Óxido Nítrico Sintasa/antagonistas & inhibidores , Óxido Nítrico Sintasa/metabolismo , Óxido Nítrico Sintasa de Tipo II , Reacción en Cadena de la Polimerasa , ARN Mensajero/genética , ARN Mensajero/metabolismo , Transcripción GenéticaRESUMEN
Fcgamma receptors on the surface of phagocytic cells bind the Fc region of IgG and mediate binding, phagocytosis, and destruction of particulate antigens opsonized by the antigen-specific IgG molecule. The present study evaluates the feasibility of converting lung epithelial cells into phagocytic cells using adenovirus (Ad) vector-mediated gene transfer of FcgammaRIIA cDNA to induce expression of the human FcgammaRIIA receptor. Binding and phagocytosis of opsonized sheep red blood cells (SRBCs) by the A549 human lung epithelial cell line after Ad-mediated FcgammaRIIA gene transfer was demonstrated using light and fluorescence microscopy and phagocytic assays with (51)Cr-labeled SRBCs. When A549 cells were infected with an Ad vector expressing a FcgammaRIIA mutant in which 2 of 3 cytoplasmic tyrosines have been replaced with phenylalanine, only binding, but not phagocytosis, of opsonized SRBCs was observed. In vivo expression of FcgammaRIIA in the lung after intratracheal administration of the AdFcgammaRIIA enhanced clearance of opsonized Pseudomonas aeruginosa from the lung in normal rats and in mice deficient in Fcgamma receptor expression. Similar results were observed with a chimeric FcgammaRIIA construct containing the extracellular domain of FcgammaRIIIA. Together, these data demonstrate that Ad-mediated FcgammaRIIA receptor cDNA expression can mediate the binding and phagocytosis of opsonized particulate antigens by normally nonphagocytic cells, suggesting that gene-transfer strategies might be used to utilize nonphagocytic cells to clear bacteria or other opsonized particulate antigens from the respiratory tract.
Asunto(s)
Técnicas de Transferencia de Gen , Pulmón/inmunología , Pulmón/microbiología , Pseudomonas aeruginosa/inmunología , Receptores de IgG/genética , Animales , Línea Celular , ADN Complementario/genética , Células Epiteliales/inmunología , Células Epiteliales/microbiología , Eritrocitos/inmunología , Humanos , Pulmón/citología , Ratones , Proteínas Opsoninas , Fagocitos/inmunología , Fagocitosis , Pseudomonas aeruginosa/patogenicidad , Ratas , Receptores de IgG/deficiencia , OvinosRESUMEN
Primary fibroblasts are not efficiently transduced by subgroup C adenovirus (Ad) vectors because they express low levels of the high-affinity Coxsackie virus and adenovirus receptor (CAR). In the present study, we have used primary human dermal fibroblasts as a model to explore strategies by which Ad vectors can be designed to enter cells deficient in CAR. Using an Ad vector expressing the human CAR cDNA (AdCAR) at high multiplicity of infection, primary fibroblasts were converted from being CAR deficient to CAR sufficient. Efficiency of subsequent gene transfer by standard Ad5-based vectors and Ad5-based vectors with alterations in penton and fiber was evaluated. Marked enhancement of binding and transgene expression by standard Ad5 vectors was achieved in CAR-sufficient fibroblasts. Expression by AdDeltaRGDbetagal, an Ad5-based vector lacking the arginine-glycine-aspartate (RGD) alphaV integrin recognition site from its penton base, was achieved in CAR-sufficient, but not CAR-deficient, cells. Fiber-altered Ad5-based vectors, including (a) AdF(pK7)betagal (bearing seven lysines on the end of fiber) (b) AdF(RGD)betagal (bearing a high-affinity RGD sequence on the end of fiber), and (c) AdF9sK betagal (bearing a short fiber and Ad9 knob), demonstrated enhanced gene transfer in CAR-deficient fibroblasts, with no further enhancement in CAR-sufficient fibroblasts. Together, these observations demonstrate that CAR deficiency on Ad targets can be circumvented either by supplying CAR or by modifying the Ad fiber to bind to other cell-surface receptors.
Asunto(s)
Adenovirus Humanos , Proteínas de la Cápside , Técnicas de Transferencia de Gen , Vectores Genéticos , Receptores Virales/metabolismo , Adenovirus Humanos/metabolismo , Cápside/genética , Cápside/metabolismo , Células Cultivadas , Fibroblastos/citología , Expresión Génica , Humanos , Receptores Virales/genética , Transgenes , Regulación hacia ArribaRESUMEN
In cardiac transplantation, chronic rejection takes the form of an occlusive vasculopathy. The mechanism underlying this disorder remains unclear. The purpose of this study was to investigate the role nitric oxide (NO) may play in the development of allograft arteriosclerosis. Rat aortic allografts from ACI donors to Wistar Furth recipients with a strong genetic disparity in both major and minor histocompatibility antigens were used for transplantation. Allografts collected at 28 d were found to have significant increases in both inducible NO synthase (iNOS) mRNA and protein as well as in intimal thickness when compared with isografts. Inhibiting NO production with an iNOS inhibitor increased the intimal thickening by 57.2%, indicating that NO suppresses the development of allograft arteriosclerosis. Next, we evaluated the effect of cyclosporine (CsA) on iNOS expression and allograft arteriosclerosis. CsA (10 mg/kg/d) suppressed the expression of iNOS in response to balloon-induced aortic injury. Similarly, CsA inhibited iNOS expression in the aortic allografts, associated with a 65% increase in intimal thickening. Finally, we investigated the effect of adenoviral-mediated iNOS gene transfer on allograft arteriosclerosis. Transduction with iNOS using an adenoviral vector suppressed completely the development of allograft arteriosclerosis in both untreated recipients and recipients treated with CsA. These results suggest that the early immune-mediated upregulation in iNOS expression partially protects aortic allografts from the development of allograft arteriosclerosis, and that iNOS gene transfer strategies may prove useful in preventing the development of this otherwise untreatable disease process.
Asunto(s)
Aorta/trasplante , Arteriosclerosis/prevención & control , Rechazo de Injerto/inmunología , Óxido Nítrico Sintasa/metabolismo , Óxido Nítrico/farmacología , Trasplante de Órganos/efectos adversos , Animales , Ciclosporina/farmacología , Terapia Genética/métodos , Antígenos de Histocompatibilidad/genética , Hiperplasia , Inmunosupresores/farmacología , Ratas , Ratas Wistar , Trasplante Homólogo , Túnica Íntima/patologíaRESUMEN
We sought to evaluate the ability of an E1(-), E3(-) adenovirus (Ad) vector (Ad(GV)CFTR.10) to transfer the normal human cystic fibrosis transmembrane conductance regulator (CFTR) cDNA to the airway epithelium of individuals with cystic fibrosis (CF). We administered Ad(GV)CFTR.10 at doses of 3 x 10(6) to 2 x 10(9) plaque-forming units over 9 months by endobronchial spray to 7 pairs of individuals with CF. Each 3-month cycle, we measured vector-derived versus endogenous CFTR mRNA in airway epithelial cells prior to therapy, as well as 3 and 30 days after therapy. The data demonstrate that (a) this strategy appears to be safe; (b) after the first administration, vector-derived CFTR cDNA expression in the CF airway epithelium is dose-dependent, with greater than 5% endogenous CFTR mRNA levels at the higher vector doses; (c) expression is transient, lasting less than 30 days; (d) expression can be achieved with a second administration, but only at intermediate doses, and no expression is observed with the third administration; and (e) the progressive lack of expression with repetitive administration does not closely correlate with induction of systemic anti-Ad neutralizing antibodies. The major advantage of an Ad vector is that it can deliver sufficient levels of CFTR cDNA to the airway epithelium so that CFTR expression protects the lungs from the respiratory manifestations of CF. However, this impressive level of expression is linked to the challenging fact that expression is limited in time. Although this can be initially overcome by repetitive administration, unknown mechanisms eventually limit this strategy, and further repetitive administration does not lead to repetitive expression.
Asunto(s)
Bronquios/metabolismo , Regulador de Conductancia de Transmembrana de Fibrosis Quística/genética , Fibrosis Quística/metabolismo , Fibrosis Quística/terapia , Terapia Genética/métodos , Tráquea/metabolismo , Adenoviridae/genética , Adolescente , Adulto , Estudios de Cohortes , Regulador de Conductancia de Transmembrana de Fibrosis Quística/administración & dosificación , Regulador de Conductancia de Transmembrana de Fibrosis Quística/inmunología , ADN Complementario/genética , Relación Dosis-Respuesta a Droga , Epitelio/metabolismo , Femenino , Vectores Genéticos/metabolismo , Humanos , Masculino , Persona de Mediana Edad , Modelos Genéticos , Reacción en Cadena de la Polimerasa , ARN Mensajero/metabolismo , Recombinación Genética , Factores de TiempoRESUMEN
We demonstrate that adenoviral-mediated gene transfer of a dominant negative rac1 gene product (N17rac1) inhibits the intracellular burst of reactive oxygen species (ROS) that occurs after reoxygenation of vascular smooth muscle cells. In contrast, expression of a dominant negative ras gene (N17ras) had no effect. Challenge of control cells and cells expressing N17rac1 with a direct oxidant stress produced an equivalent increase in intracellular ROS levels and subsequent cell death. This suggests that N17rac1 expression appears to block production of harmful oxygen radicals and does not act directly or indirectly to scavenge ROS generated during reoxygenation. Expression of N17rac1 results in protection from hypoxia/reoxygenation-induced cell death in a variety of cell types including vascular smooth muscle cells, fibroblasts, endothelial cells, and ventricular myocytes. These results suggest that reoxygenation injury requires the activation of rac proteins, and that inhibition of rac-dependent pathways may be a useful strategy for the prevention of reperfusion injury in ischemic tissues.
Asunto(s)
Proteínas de Unión al GTP/antagonistas & inhibidores , Músculo Liso Vascular/efectos de los fármacos , Oxígeno/farmacología , Aerobiosis , Anaerobiosis , Animales , Aorta/citología , Muerte Celular/efectos de los fármacos , Células Cultivadas , Depuradores de Radicales Libres , Proteínas de Unión al GTP/genética , Humanos , Músculo Liso Vascular/patología , Ratas , Especies Reactivas de Oxígeno/metabolismo , Proteínas Recombinantes/antagonistas & inhibidores , Daño por Reperfusión/prevención & control , Transducción de Señal , Venas Umbilicales/citología , Proteínas de Unión al GTP rac , Proteínas ras/metabolismoRESUMEN
We have used adenoviral-mediated gene transfer of a constitutively active (V12rac1) and dominant negative (N17rac1) isoform of rac1 to assess the role of this small GTPase in cardiac myocyte hypertrophy. Expression of V12rac1 in neonatal cardiac myocytes results in sarcomeric reorganization and an increase in cell size that is indistinguishable from ligand-stimulated hypertrophy. In addition, V12rac1 expression leads to an increase in atrial natriuretic peptide secretion. In contrast, expression of N17rac1, but not a truncated form of Raf-1, attenuated the morphological hypertrophy associated with phenylephrine stimulation. Consistent with the observed effects on morphology, expression of V12rac1 resulted in an increase in new protein synthesis, while N17rac1 expression inhibited phenylephrine-induced leucine incorporation. These results suggest rac1 is an essential element of the signaling pathway leading to cardiac myocyte hypertrophy.
Asunto(s)
Cardiomegalia/fisiopatología , Proteínas de Unión al GTP/fisiología , Miocardio/citología , Transducción de Señal/fisiología , Adenoviridae/genética , Animales , Animales Recién Nacidos , Factor Natriurético Atrial/metabolismo , Proteínas Quinasas Dependientes de Calcio-Calmodulina/análisis , Tamaño de la Célula/fisiología , Células Cultivadas , Técnica del Anticuerpo Fluorescente , GTP Fosfohidrolasas/fisiología , Regulación de la Expresión Génica/fisiología , Técnicas de Transferencia de Gen , Fenilefrina/farmacología , Biosíntesis de Proteínas , Proteínas Proto-Oncogénicas c-raf/fisiología , Ratas , Ratas Sprague-Dawley , Sarcómeros/ultraestructura , Proteínas de Unión al GTP racRESUMEN
A novel practical method for the synthesis of N-methyl-DL-aspartic acid 1 (NMA) and new syntheses for N-methyl-aspartic acid derivatives are described. NMA 1, the natural amino acid was synthesized by Michael addition of methylamine to dimethyl fumarate 5. Fumaric or maleic acid mono-ester and -amide were regioselectively transformed into beta-substituted aspartic acid derivatives. In the cases of maleamic 11a or fumaramic esters 11b, the alpha-amide derivative 13 was formed, but hydrolysis of the product provided N-methyl-DL-asparagine 9 via base catalyzed ring closure to DL-alpha-methylamino-succinimide 4, followed by selective ring opening. Efficient methods were developed for the preparation of NMA-alpha-amide 13 from unprotected NMA via sulphinamide anhydride 15 and aspartic anhydride 3 intermediate products. NMA diamide 16 was prepared from NMA dimethyl ester 6 and methylamino-succinimide 4 by ammonolysis. Temperature-dependent side reactions of methylamino-succinimide 4 led to diazocinone 18, resulted from self-condensation of methylamino-succinimide via nucleophyl ring opening and the subsequent ring-transformation.
Asunto(s)
N-Metilaspartato/análogos & derivados , N-Metilaspartato/síntesis química , Aminoácidos/química , Asparagina/química , Ésteres/química , Espectrometría de Masas , Succinimidas/químicaRESUMEN
Actin coding sequence cDNA probes were used to quantitate the number of transcripts in RNA from eggs, embryos, and tube feet of the sea star Pisaster ochraceus. Transcript concentrations were measured in both total RNA and in poly(A)+ RNA by titration and hybridization kinetic methods. Surprisingly, the actin transcript number in sea star eggs is two orders of magnitude greater than in sea urchin eggs. There are at least 2.9 X 10(5) actin transcripts per sea star egg, 1.2 X 10(5) per 48-h gastrula and 1.9 X 10(5) per 72-h gastrula. The number of actin transcripts per unit mass of extracted tube foot RNA is lower than in developmental stages. The relative abundance and size of actin transcripts was determined by Northern and dot blot analyses using probes containing actin coding DNA or 3'-untranslated-region sequences. The actin transcript in eggs and embryos is 2,300 nucleotides (nt) long and originates from the Cy (cytoplasmic) gene class. In tube feet, the most abundant actin transcript is 2,200 nt long and originates from the M (muscle) gene class. Tube feet also contain, at lower abundance, 2,300-nt transcripts of the Cy gene type expressed in eggs and embryos.
Asunto(s)
Actinas/genética , Equinodermos/genética , Genes , Óvulo/metabolismo , Transcripción Genética , Animales , Clonación Molecular , ADN/metabolismo , Enzimas de Restricción del ADN , Embrión no Mamífero/metabolismo , Femenino , Hibridación de Ácido NucleicoRESUMEN
Adenovirus (Ad) is used as a vector for gene delivery in therapies involving genetic disease, vascular disease, and cancer. The first step for efficient gene transfer is effective virus binding to the target cells. We have found that Ad-mediated gene delivery to multiple cell types is much less efficient compared to epithelial-derived cells. Low gene delivery to nonepithelial cell types was directly correlated to a deficiency of the cellular receptor which mediates Ad binding. To overcome this inefficiency we constructed a new virus, AdPK, that contains a heparin-binding domain that targets the virus to broadly expressed, heparan-containing cellular receptors. AdPK delivers genes to multiple cell types at markedly higher efficiencies than unmodified Ad. Viruses with enhanced attachment characteristics significantly improve gene transfer efficiency and may expand the tissues amenable to efficient Ad-mediated gene therapy.
Asunto(s)
Adenoviridae/genética , Adenoviridae/metabolismo , Heparina/metabolismo , Músculo Liso Vascular/metabolismo , Secuencia de Aminoácidos , Animales , Fibroblastos/metabolismo , Técnicas de Transferencia de Gen , Terapia Genética , Datos de Secuencia Molecular , Mutación/genética , beta-GalactosidasaRESUMEN
Epidermal Growth Factor Receptor (EGFR) is a high priority target in anticancer drug research. Thousands of very effective EGFR inhibitors have been developed in the last decade. The known inhibitors are originated from a very diverse chemical space but--without exception--all of them act at the Adenosine TriPhosphate (ATP) binding site of the enzyme. We have collected all of the diverse inhibitor structures and the relevant biological data obtained from comparable assays and built prediction oriented Quantitative Structure-Activity Relationship (QSAR) which models the ATP binding pocket's interactive surface from the ligand side. We describe a QSAR method with automatic Variable Subset Selection (VSS) by Genetic Algorithm (GA) and goodness-of-prediction driven QSAR model building, resulting an externally validated EGFR inhibitory model built from pIC50 values of a diverse structural set of 623 EGFR inhibitors. Repeated Trainings/Evaluations (RTE) were used to obtain model fitness values and the effectiveness of VSS is amplified by using predictive ability scores of descriptors. Numerous models were generated by different methods and viable models were collected. Then, intensive RTE were applied to identify ultimate models for external validations. Finally, suitable models were validated by statistical tests. Since we use calculated molecular descriptors in the modeling, these models are suitable for virtual screening for obtaining novel potential EGFR inhibitors.
Asunto(s)
Receptores ErbB/antagonistas & inhibidores , Inhibidores Enzimáticos/química , Inhibidores Enzimáticos/farmacología , Humanos , Modelos Moleculares , Relación Estructura-Actividad CuantitativaRESUMEN
Human metastasis-suppressor genes nm23-1 (NME1) and nm23-2 (NME2) are implicated in control of the metastatic potential of malignant cells. Using somatic cell hybrid analysis and fluorescence in situ hybridization we co-localized both genes to 17q21.3. The 17q21 region carries the locus responsible for early-onset familial breast-ovarian cancer and several other genes that are involved in tumorigenesis and differentiation and undergo frequent rearrangements during neoplastic development. Thus, our mapping places the NME genes in a region that may be subjected to multiple selection pressures. NME1 and NME2 genes were expressed as soluble proteins in a T7 bacterial expression system. Both proteins are independently active nucleotide diphosphate kinases and readily form intra- and intermolecular disulfide bonds. The biochemical properties of these proteins may explain the diversity of mature eucaryotic nucleoside diphosphate kinases.
Asunto(s)
Mapeo Cromosómico , Genes Supresores de Tumor , Metástasis de la Neoplasia , Nucleósido-Difosfato Quinasa/análisis , Animales , Secuencia de Bases , Humanos , Ratones , Datos de Secuencia Molecular , Proteínas Recombinantes/análisisRESUMEN
Genomic and tube foot cDNA recombinant libraries have been prepared from the sea star Pisaster ochraceus. Three major classes of actin-bearing lambda phage clones have been identified on the basis of restriction enzyme mapping and localization of actin coding regions. There are at most six non-allelic actin genes in the sea star genome. Southern blots of restriction enzyme-digested genomic DNA from individual sea stars probed with actin coding sequences indicate extensive polymorphism in actin gene regions. The locations of repetitive sequences within the genomic clones have been mapped. Approx. 1% of cDNA clones prepared from tube foot poly(A) RNA contain actin coding segments. The actin gene(s) from which the tube foot actin transcripts originate have been identified by hybridization with a 460 bp 3' untranslated region from one of the cDNA plasmids. Hybridization of the untranslated region probe with genomic digests demonstrates that there are at least three alleles for the tube foot actin in sea star populations.
Asunto(s)
Actinas/genética , Genes , Estrellas de Mar/genética , Animales , Mapeo Cromosómico , ADN/genética , Regulación de la Expresión Génica , Ligamiento Genético , Hibridación de Ácido Nucleico , Polimorfismo Genético , Secuencias Repetitivas de Ácidos Nucleicos , Estrellas de Mar/anatomía & histologíaRESUMEN
BACKGROUND: Administration of angiogenic factors stimulates neovascularization in ischemic tissues. However, there is no evidence that angiogenesis can be induced in normoperfused skeletal muscles. We tested the hypothesis that adenovirus-mediated intramuscular (IM) gene transfer of the 121-amino-acid form of vascular endothelial growth factor (AdCMV.VEGF(121)) could stimulate neovascularization in nonischemic skeletal muscle and consequently attenuate the hemodynamic deficit secondary to surgically induced ischemia. METHODS AND RESULTS: Rabbits and rats received IM injections of AdCMV.VEGF(121), AdCMV.Null, or saline in the thigh, 4 weeks (rabbits) or 2 weeks (rats) before femoral artery removal in the injected limb. In unoperated rats, at the site of injection of AdCMV.VEGF(121), we found 96% and 29% increases in length density of arterioles and capillaries, respectively. Increased tissue perfusion (TP) to the ischemic limb in the AdCMV.VEGF(121) group was documented, as early as day 1 after surgery, by improved blood flow to the ischemic gastrocnemius muscle measured by radioactive microspheres (AdCMV.VEGF(121)=5.69+/-0.40, AdCMV.Null=2.97+/-0.50, and saline=2.78+/-0.43 mL x min(-1) x 100 g(-1), P<0.001), more angiographically recognizable collateral vessels (angioscore) (AdCMV. VEGF(121)=50.58+/-1.48, AdCMV.Null=29.08+/-4.22, saline=11.83+/-1.90, P<0.0001), and improvement of the bioenergetic reserve of the gastrocnemius muscle as assessed by (31)P NMR spectroscopy. Follow-up studies showed that superior TP to the ischemic limb in the AdCMV.VEGF(121) group persisted until it was equalized by spontaneous collateral vessel development in untreated animals. CONCLUSIONS: IM administration of AdCMV.VEGF(121) stimulates angiogenesis in normoperfused skeletal muscles, and the newly formed vessels preserve TP after induction of ischemia.
Asunto(s)
Arteriolas/fisiología , Capilares/fisiología , Factores de Crecimiento Endotelial/genética , Técnicas de Transferencia de Gen , Isquemia/fisiopatología , Isquemia/terapia , Linfocinas/genética , Músculo Esquelético/irrigación sanguínea , Neovascularización Fisiológica , Adenoviridae , Animales , Citomegalovirus/genética , Arteria Femoral/fisiología , Terapia Genética/métodos , Vectores Genéticos , Hemodinámica/fisiología , Masculino , Conejos , Ratas , Ratas Wistar , Factor A de Crecimiento Endotelial Vascular , Factores de Crecimiento Endotelial VascularRESUMEN
OBJECTIVES: To test the feasibility of myocardial angiogenic gene expression using a novel catheter-based transendocardial injection system. BACKGROUND: Angiogenesis has been induced by direct injection of growth factors into ischemic myocardium during open-heart surgery. Catheter-based transendocardial injection of angiogenic factors may provide equivalent benefit without need of surgery. METHODS: A new guidance system for intramyocardial therapy utilizes magnetic fields and catheter-tip sensors to locate a position in space and reconstruct three-dimensional left ventricular (LV) electromechanical maps without using fluoroscopy. A retractable 27G needle was coupled with the guidance system for LV transendocardial injection. In 12 pigs, the catheter was used to inject 0.1 ml of methylene-blue (MB) dye and 8 pigs had myocardial injections of adenoviral vector (1 x 10(10) particles per site) containing the LacZ transgene. Ten pigs underwent catheter-based transendocardial injection and six pigs were injected using transepicardial approach with the gene encoding adenovirus vascular endothelial growth factor-121 (Ad.VEGF121; 1 x 10(10) viral particles x 6 sites) and sacrificed at 24 h. Injection sites were identified with ultraviolet light by coinjection of fluorescent beads. RESULTS: Overall, 138 of 152 attempted injection MB tracks (91%) were found after sacrifice. Tissue staining was 7.1+/-2.1 mm in depth and 2.3+/-1.8 mm in width. No animal had pericardial effusion or tamponade. In Ad.LacZ injected animals, gross pathology showed positive staining in injected zones, and histology confirmed positive myocyte staining. Adenovirus vascular endothelial growth factor-121 injected sites showed high levels of VEGF121 production that was of similar magnitude whether injected using the transendocardial (880.4+/-412.2 pg VEGF121/mg protein) or transepicardial (838.3+/-270 pg VEGF121/mg protein) delivery approach (p = 0.62). CONCLUSIONS: Using this magnetic guidance catheter-based navigational system, transgenes can effectively be transfected into designated myocardial sites. Thus, if it is determined that direct intramyocardial injection of angiogenic factors enhances collateral function in patients, this less invasive catheter-based system offers a similar gene delivery efficiency and, thus, may have clear advantages compared with the surgically-based transepicardial injection approach.
Asunto(s)
Mapeo del Potencial de Superficie Corporal/instrumentación , Cateterismo Cardíaco/instrumentación , Factores de Crecimiento Endotelial/administración & dosificación , Terapia Genética/instrumentación , Procesamiento de Imagen Asistido por Computador/instrumentación , Linfocinas/administración & dosificación , Isquemia Miocárdica/terapia , Animales , Circulación Coronaria/genética , Endocardio/patología , Factores de Crecimiento Endotelial/genética , Diseño de Equipo , Estudios de Factibilidad , Técnicas de Transferencia de Gen/instrumentación , Inyecciones , Linfocinas/genética , Isquemia Miocárdica/genética , Isquemia Miocárdica/patología , Pericardio/patología , Factor A de Crecimiento Endotelial Vascular , Factores de Crecimiento Endotelial VascularRESUMEN
Adenoviruses began to be developed into highly effective gene expression vectors in the early 1980s. Recently, the increased interest in utilizing this transfer system in vivo has posed new problems for heterologous gene-transfer, spurring a renewed effort in the field of vector development toward solving the structural, immunological and targeting problems posed by gene therapy applications.